Literature DB >> 6271691

The analgesic effect of calcitonin in humans: studies on the role of opioid peptides.

A Fabbri, C Santoro, C Moretti, M Cappa, F Fraioli, G P Di Julio, T Galluzzi, V La Manna.   

Abstract

The possibility that the analgesic action of calcitonin could be due to variations in beta-endorphin levels in both peripheral blood and cerebrospinal fluid was studied. A total of 40 microgram of synthetic salmon calcitonin was injected i. v. in four male volunteers undergoing minor operations under rachianesthesia. Beta-Endorphin was determined in blood and cerebrospinal fluid samples that were collected before and at regular intervals after calcitonin injection. No statistically significant variation in beta-endorphin levels was observed either in peripheral blood or cerebrospinal fluid. Since the injected calcitonin was free of contaminants (demonstrated by both high pressure liquid chromatography and radioimmunoassay of endorphin made on the injected preparation) and since an increase was observed in the immunoreactive calcitonin in cerebrospinal fluid following calcitonin i. v., self-analgesic action may be hypothesized, even though action through prostaglandins or other systems cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6271691

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  6 in total

1.  Increase of pain threshold by calcitonin during electrical stimulation of the dental pulp. Investigations in healthy volunteers with regard to plasma concentration.

Authors:  K Welzel; D Welzel
Journal:  Schmerz       Date:  1989-09       Impact factor: 1.107

2.  Plasma beta-endorphin, ACTH and cortisol secretion in man after nasal spray administration of calcitonin.

Authors:  R Franceschini; A Cataldi; T Barreca; M Salvemini; E Rolandi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 3.  Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Authors:  S P Clissold; A Fitton; P Chrisp
Journal:  Drugs Aging       Date:  1991 Sep-Oct       Impact factor: 3.923

4.  [Calcitonin.].

Authors:  C Maier
Journal:  Schmerz       Date:  1990-03       Impact factor: 1.107

5.  Long- and short-term side effects and safety of calcitonin in man: a prospective study.

Authors:  S J Wimalawansa
Journal:  Calcif Tissue Int       Date:  1993-02       Impact factor: 4.333

6.  Antiserotonergic inhibition of calcitonin-induced increase of beta-endorphin, ACTH, and cortisol secretion.

Authors:  L Laurian; Z Oberman; E Hoerer; E Graf
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.